MARKET

OMER

OMER

Omeros
NASDAQ
5.83
+0.05
+0.78%
Opening 12:09 05/30 EDT
OPEN
5.79
PREV CLOSE
5.78
HIGH
5.89
LOW
5.78
VOLUME
100.76K
TURNOVER
383.55K
52 WEEK HIGH
7.75
52 WEEK LOW
1.735
MARKET CAP
365.98M
P/E (TTM)
7.82
1D
5D
1M
3M
1Y
5Y
Omeros: Report of proposed sale of securities
Press release · 2d ago
Russell 3000 rejig: InMode, Assertio among healthcare additions; Inovio, Bionano among deletions
Seeking Alpha · 5d ago
Omeros: Statement of changes in beneficial ownership of securities
Press release · 6d ago
Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023
Seeking Alpha · 05/16 22:55
BRIEF-Omeros Corp - On May 12, Board Increased Number Of Its Directors To Nine
Reuters · 05/16 21:30
Omeros: Initial statement of beneficial ownership of securities
Press release · 05/16 18:33
Omeros: Current report
Press release · 05/16 17:11
Omeros: Q1 Earnings Insights
Benzinga · 05/09 21:16
More
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.